Trial
NCT07134556
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
MedSIR
Collaborators
—
Condition
Triple Negative Breast Cancer
Intervention
Zimberelimab (AB122)
Why stopped
The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve overall survival compared to standard of care.
No new relevant safety concerns were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-01